Angiodroid SpA

Key People

• Sebastiano Zannoli - CEO & Founder
• Marzia Tavernese - Quality and Regulatory Affairs Manager
• Lorenzo Casadei - Product Development Manager
• Massimo Ceccarelli - Board Member
• Francesca Natali - Board Member
• Valerio Caracciolo - Board Member
• Andrea Venturelli - Board Member
• Mario Scuderi - Board Member

Assessment

Team

Aspect: Multiple successful MedTech entrepreneurs
Summary: The leadership team comprises experienced professionals with significant backgrounds in the medical device industry.

The presence of multiple successful MedTech entrepreneurs, including individuals with over 30 years in the medical device industry and founders of companies acquired by major players like Medtronic, indicates a strong leadership team capable of navigating the complexities of the medical device market.

Clinical Need

Aspect: Very Strong
Summary: Angiodroid addresses a significant clinical need by providing a safer alternative to iodine-based contrast media for angiography.

With over 200 million angiograms performed worldwide annually and approximately 30% of patients at risk of contrast-induced acute kidney injury, Angiodroid's CO2 injector offers a biocompatible alternative, addressing a substantial unmet clinical need.

Competition

Aspect: First mover
Summary: Angiodroid is the first to market with an automatic CO2 injector for angiography, providing a unique solution.

As the pioneer in automatic CO2 injection systems for angiography, Angiodroid faces the task of educating the market and establishing trust in its technology, which can be resource-intensive and time-consuming.

Technical Challenge

Aspect: Predictable
Summary: The technical challenges associated with developing the CO2 injector are manageable and well-understood.

The development of the CO2 injector involves predictable engineering challenges, which the company has effectively addressed, resulting in a commercially available product.

Patent

Aspect: Strong
Summary: Angiodroid holds patents in Europe and the US, with pending patents in China, providing robust intellectual property protection.

The granted patents in key markets and pending patents in China offer significant protection against competitors, allowing Angiodroid to maintain a unique position in the market.

Financing

Aspect: Well-funded
Summary: The company has secured substantial funding, including a 7 million Series A round in 2023.

The 7 million Series A financing, led by prominent investors, equips Angiodroid with the necessary capital to enhance its global presence and advance its product pipeline.

Regulatory

Aspect: 510k/PMA
Summary: Angiodroid's products have obtained regulatory approvals in multiple regions, facilitating market entry.

Securing regulatory clearances in various jurisdictions enables Angiodroid to market its products globally, ensuring compliance with medical device standards and facilitating adoption by healthcare providers.

Opportunity Rollup

Odds of Success

3.3

Peak Market Share

3.9

Segment CAGR

4.0%

Market Segment

Cardiovascular Devices

Market Sub Segment

Interventional Cardiology

Key Takeaway

Angiodroid's innovative CO2 injector addresses a significant clinical need, supported by a strong team and recent funding, positioning the company well for growth in the cardiovascular device market.